61.33
price down icon0.89%   -0.55
after-market After Hours: 61.65 0.32 +0.52%
loading
Rhythm Pharmaceuticals Inc stock is traded at $61.33, with a volume of 484.16K. It is down -0.89% in the last 24 hours and down -5.96% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$61.88
Open:
$61.53
24h Volume:
484.16K
Relative Volume:
0.71
Market Cap:
$3.90B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-21.83
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
-1.65%
1M Performance:
-5.96%
6M Performance:
-1.14%
1Y Performance:
+67.20%
1-Day Range:
Value
$60.32
$61.78
1-Week Range:
Value
$58.71
$63.66
52-Week Range:
Value
$35.56
$68.58

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
Name
Rhythm Pharmaceuticals Inc
Name
Phone
857-264-4280
Name
Address
222 BERKELEY STREET, BOSTON, MA
Name
Employee
283
Name
Twitter
@rhythmpharma
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
RYTM's Discussions on Twitter

Compare RYTM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
61.33 3.97B 136.86M -168.69M -113.49M -2.81
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-07-25 Upgrade BofA Securities Neutral → Buy
Mar-05-25 Resumed Stifel Buy
Jan-02-25 Initiated Jefferies Buy
Dec-20-24 Initiated Oppenheimer Outperform
Oct-21-24 Initiated Guggenheim Buy
Sep-18-24 Initiated H.C. Wainwright Buy
Sep-17-24 Initiated JMP Securities Mkt Outperform
May-08-24 Downgrade BofA Securities Buy → Neutral
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-01-23 Upgrade BofA Securities Neutral → Buy
Jan-18-23 Resumed Canaccord Genuity Buy
Aug-08-22 Upgrade Goldman Neutral → Buy
Aug-05-22 Upgrade BofA Securities Underperform → Neutral
Jun-17-22 Reiterated Needham Buy
Mar-02-22 Resumed Stifel Buy
Feb-17-22 Upgrade Ladenburg Thalmann Neutral → Buy
Dec-08-21 Initiated Wells Fargo Overweight
Nov-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-14-21 Resumed Goldman Neutral
Aug-04-21 Downgrade BofA Securities Neutral → Underperform
Aug-04-21 Downgrade Ladenburg Thalmann Buy → Neutral
Nov-30-20 Downgrade BofA Securities Buy → Neutral
Jan-08-20 Initiated Goldman Sell
Jul-12-19 Upgrade Stifel Hold → Buy
Jul-08-19 Initiated Canaccord Genuity Buy
Mar-13-19 Initiated Ladenburg Thalmann Buy
Sep-07-18 Resumed Morgan Stanley Overweight
Jun-25-18 Reiterated Needham Buy
Jun-15-18 Reiterated Needham Buy
Oct-30-17 Initiated BofA/Merrill Buy
Oct-30-17 Initiated Needham Buy
View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

pulisher
May 30, 2025

Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

Stifel Nicolaus Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World

May 30, 2025
pulisher
May 29, 2025

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga

May 29, 2025
pulisher
May 29, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Analyst | RYTM Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 29, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News - GuruFocus

May 29, 2025
pulisher
May 28, 2025

Ameriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 28, 2025
pulisher
May 27, 2025

POMC Deficiency Obesity Market on Track for Major Expansion - openPR.com

May 27, 2025
pulisher
May 24, 2025

(RYTM) Investment Analysis - news.stocktradersdaily.com

May 24, 2025
pulisher
May 22, 2025

Deutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 22, 2025
pulisher
May 21, 2025

Gotham Asset Management LLC Sells 2,685 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 21, 2025
pulisher
May 21, 2025

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $75.38 Consensus Price Target from Analysts - Defense World

May 21, 2025
pulisher
May 14, 2025

Rhythm Pharmaceuticals Announces New Data Presentations on Patie - GuruFocus

May 14, 2025
pulisher
May 14, 2025

(RYTM) On The My Stocks Page - news.stocktradersdaily.com

May 14, 2025
pulisher
May 14, 2025

RYTM Shows Positive Results in Hypothalamic Obesity Treatment | - GuruFocus

May 14, 2025
pulisher
May 14, 2025

RYTM Shows Positive Results in Hypothalamic Obesity Treatment | RYTM Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3 - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Raymond James Financial Inc. Buys New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 13, 2025
pulisher
May 12, 2025

Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN

May 12, 2025
pulisher
May 12, 2025

HC Wainwright Has Negative Estimate for RYTM Q2 Earnings - Defense World

May 12, 2025
pulisher
May 09, 2025

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 6.6% on Disappointing Earnings - Defense World

May 09, 2025
pulisher
May 09, 2025

Needham & Company LLC Increases Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $72.00 - Defense World

May 09, 2025
pulisher
May 09, 2025

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 09, 2025
pulisher
May 08, 2025

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals Q1 2025 slides: Revenue grows 45% as HO program advances - Investing.com Canada

May 07, 2025
pulisher
May 07, 2025

RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals (RYTM) Price Target Raised by Needham | RYTM Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals' Q1 Net Loss Narrows, Revenue Increases - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

RYTM Misses Q1 Revenue Estimates, Focuses on Future Therapies for Hypothalamic Obesity | RYTM Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals Reports Q1 2025 Earnings: EPS of ($0.81) Misses Estimate, Revenue of $37.7 Million Below Expectations - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - The Manila Times

May 07, 2025
pulisher
May 07, 2025

Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q1 Loss $0.81, vs. FactSet Est of $0.73 Loss - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

BRIEF-Rhythm Pharmaceuticals Q1 Net Income USD -49.498 Million - TradingView

May 07, 2025
pulisher
May 06, 2025

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Rare Disease Leader Rhythm Pharmaceuticals Lines Up Triple Conference Appearances in Healthcare Circuit - Stock Titan

May 06, 2025
pulisher
May 06, 2025

Mariner LLC Invests $254,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

May 06, 2025
pulisher
May 05, 2025

Rhythm Pharmaceuticals (RYTM) Expected to Announce Earnings on Wednesday - Defense World

May 05, 2025
pulisher
May 04, 2025

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up - simplywall.st

May 04, 2025
pulisher
May 04, 2025

(RYTM) Trading Report - news.stocktradersdaily.com

May 04, 2025
pulisher
Apr 30, 2025

BlackRock, Inc. Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

Obesity Market Set to Grow Substantially Through 2034, - openPR.com

Apr 30, 2025
pulisher
Apr 26, 2025

Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - MSN

Apr 26, 2025
pulisher
Apr 26, 2025

Wells Fargo & Company MN Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $74.92 - Defense World

Apr 26, 2025

Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Cap:     |  Volume (24h):